ArticleVirchows Archiv : an international journal of pathology2006
Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases.
Article in Virchows Archiv : an international journal of pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- Primary ocular-adnexal non-Hodgkin Lymphoma in a Peruvian cohort: An 18-year experience.PloS one · 2026Article
- Clinical Patterns and Prognostic Outcomes of Asian Ocular Adnexal Marginal Zone Lymphoma.Journal of hematology · 2025Article
- Retrospective Evaluation of Clinical, Demographic, and Radiological Data of Orbital Lymphoma Patients: A Single Tertiary Center Experience.Beyoglu eye journal · 2025Article
- Extra-Nodal Marginal Zone Lymphoma (MZL) of MALT CD20+ of the Ocular Adnexa: Case Report.Maedica · 2020Article
- Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China.International journal of ophthalmology · 2019Article
- Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.Clinical and experimental medicine · 2018Review
- Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy.Mediterranean journal of hematology and infectious diseases · 2016Review
- Choroidal and adnexal extranodal marginal zone B-cell lymphoma: presentation, imaging findings, and therapeutic management in a series of nine cases.Eye (London, England) · 2013Article
- Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.British journal of haematology · 2011Article
- Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland: sustained remission after eradication of helicobacter pylori infection.Case reports in gastrointestinal medicine · 2011Article
- Review
- Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland.The British journal of ophthalmology · 2007Article
- Primary mantle cell lymphoma of the conjunctiva: a case report.Virchows Archiv : an international journal of pathology · 2006Article
- Article
- The role of infectious agents in the etiology of ocular adnexal neoplasia.Survey of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To better characterize ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue (MZL-MALT), we analyzed the clinical and pathologic features of 23 patients (11 men, 12 women, median age 66 years). The tumor was confined to one ocular structure in 18 cases (conjunctiva, n=8; orbit, n=8; or lacrimal gland, n=2). Concurrent extraorbital disease was detected by the staging procedure in five patients, and preferentially involved other MALT sites. Histogenetic B cell marker studies, available in 13 cases, showed an early post-germinal center (GC) phenotype (BCL-6(-)/IRF4(+)/CD138(-)) (n=5) or a late post-GC phenotype (BCL-6(-)/IRF4(+)/CD138(+)) (n=8), which could be helpful for discrimination from other types of small-B cell lymphoma. BCL10 was positive in 12 of 13 patients tested, with nuclear (n=4) or cytoplasmic (n=8) immunoreactivity. These staining patterns ruled out t(1;14)(p22;q32) translocation. T(11;18)(q21;q21), another MZL-MALT-specific translocation, was detected by reverse transcriptase polymerase chain reaction in four of 15 patients tested. Clinical outcome was excellent but the overall relapse rate was 26.1% with a median follow-up of 39 months (range 6-132 months). Regardless of the disease stage at diagnosis, combined chemotherapy and radiotherapy seemed to be more effective than chemotherapy alone in ocular adnexal MZL-MALT, as persistent complete remission was achieved in nine patients receiving combination therapy, while six of 14 patients treated with chemotherapy alone relapsed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.